ClinicalTrials.gg
CompletedNCT02183506Updated Jul 8, 2014

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

A Phase 1 interventional study of Metformin and BI 1356 BS in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
Male
01

Study summary

Investigate the bioavailability of BI 1356 BS and of metformin after concomitant multiple oral administration of 10 mg BI 1356 BS tablets and 3 x 850 mg metformin in comparison to BI 1356 BS and metformin given alone

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males according to the following criteria, based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), clinical laboratory tests

    • No finding deviating from normal and of clinical relevance
    • No evidence of a concomitant disease
  • Age ≥ 21 and Age ≤ 50 years
  • (Body Mass Index) ≥ 18.5 and ≤ 29.9 kg/m2
  • Ability to give signed and dated written prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial by the investigator
  • Intake of drugs with a long half-life (>24 hours) within one month or less than 10 half-lives of the respective drug prior to administration or during the conduct of this trial (review with clinical monitor if there is a question)
  • Use of drugs which might reasonably influence the results of the trial (based on knowledge at the time of protocol preparation) within 10 days prior to administration or during the conduct of this trial
  • Participation in another trial with an drug within two months prior to administration or during the conduct of this trial
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking during the conduct of this trial
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the conduct of this trial)
  • Excessive physical activities (within one week prior to administration or during the conduct of this trial)
  • Any laboratory value outside the normal reference range that is of clinical relevance
  • Inability to comply with the dietary regimen of the study center
  • No adequate (condom use plus another form of contraception e.g., spermicide, oral contraceptive taken by female partner, sterilization) during the whole study period from the time of the first intake of study drug until one month after the last intake of drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Metformin

    Drug: Metformin

  • Experimental
    BI 1356 BS and metformin

    Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)

    Drug: Metformin · Drug: BI 1356 BS

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) of the analytes in plasma at different time points

    Time frame: up to 240 hours after start of treatment

  2. Maximum concentration (Cmax) of the analytes in plasma at different time points

    Time frame: up to 240 hours after start of treatment

Secondary outcomes

  1. Time from last dosing to maximum concentration of the analytes in plasma at steady state (tmax,ss)

    Time frame: up to 240 hours after start of treatment

  2. Minimum concentration of the analytes in plasma at steady state (Cmin,ss) over a uniform dosing interval τ

    Time frame: up to 240 hours after start of treatment

  3. Terminal rate constant of the analytes in plasma at steady state (λz,ss )

    Time frame: up to 240 hours after start of treatment

  4. Terminal half-life of the analytes in plasma at steady state (t1/2,ss )

    Time frame: up to 240 hours after start of treatment

  5. Mean residence time of the analytes in the body at steady state after oral administration (MRTpo,ss)

    Time frame: up to 240 hours after start of treatment

  6. Apparent clearance of the analytes in the plasma at steady state (CL/F,ss) following extravascular multiple dose administration

    Time frame: up to 240 hours after start of treatment

  7. Apparent volume of distribution during the terminal phase λz at steady state (Vz/F,ss) following extravascular administration

    Time frame: up to 240 hours after start of treatment

  8. Measurements of dipeptidylpeptidase 4 (DPP-IV) activity

    Time frame: up to 240 hours after start of treatment

  9. Number of patients with adverse events

    Time frame: up to 60 days

  10. Number of patients with clinically abnormal changes in laboratory values

    Time frame: Baseline, up to 14 days after last drug administration

  11. Number of patients with clinically relevant changes in vital signs

    Time frame: Baseline, up to 14 days after last drug administration

  12. feτ,ss (fraction of the dose excreted unchanged in urine at steady state)

    Time frame: 0-4 h, 4-8 h, 8-12 h and 12-24 hours after drug administration on days 3, 6, 9

  13. CLR,ss (renal clearance of the analyte in plasma at steady state)

    Time frame: 0-4 h, 4-8 h, 8-12 h and 12-24 hours after drug administration on days 3, 6, 9

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Sep 2005
Primary completionActual
Dec 2005
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183506
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Sep 2005
Primary completion
Dec 2005
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion